The somatic activating janus kinase 2 mutation (JAK2)V617F is detectable in most patients with polycythemia vera (PV). Enzymatic assays indicate that both JAK1 and JAK2 are 100- and 20-fold less sensitive to inhibition by CP- 690,550, respectively, when compared with JAK3. JAK2V617F-bearing cells were almost 10-fold more sensitive to CP-690,550 compared with JAK2WT cells, with IC50s of 0.25 ¦ÌM and 2.11 ¦ÌM, respectively

June 21, 2017

prudect name : The somatic activating janus kinase 2 mutation (JAK2)V617F is detectable in most patients with polycythemia vera (PV). Enzymatic assays indicate that both JAK1 and JAK2 are 100- and 20-fold less sensitive to inhibition by CP- 690,550, respectively, when compared with JAK3. JAK2V617F-bearing cells were almost 10-fold more sensitive to CP-690,550 compared with JAK2WT cells, with IC50s of 0.25 ¦ÌM and 2.11 ¦ÌM, respectively
CP 690550

Synonyms: TasocitinibCAS NO: 477600-75-2Molecular Formula: C₁₆H₂₀N₆OMolecular Weight: 312.37Purity: 98% minSolubility: In DMSOStorage: −20°C

XL335 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18509461/